Publications by authors named "Kei Furihata"
Article Synopsis
- DS-5670 is an mRNA vaccine targeting the spike protein of SARS-CoV-2, showing safety and effectiveness in adults for COVID-19 booster vaccination.
- A study with children aged 5-11 years assessed a third booster of either DS-5670a/b or bivalent BNT162b2 after initial vaccination, measuring blood neutralization response to variants.
- Results indicated DS-5670a/b produced a comparable immune response to BNT162b2, exceeding safety benchmarks with no new safety concerns noted among the pediatric participants.
Background: DS-5670a is a vaccine candidate for coronavirus disease 2019 (COVID-19) harnessing a novel modality composed of messenger ribonucleic acid (mRNA) encoding the receptor-binding domain (RBD) from the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) encapsulated in lipid nanoparticles. Here, we report the safety, immunogenicity, and pharmacokinetic profile of DS-5670a from a phase 2 clinical trial in healthy adults who were immunologically naïve to SARS-CoV-2.
Methods: The study consisted of an open-label, uncontrolled, dose-escalation part and a double-blind, randomized, uncontrolled, 2-arm, parallel-group part.
Zinc intake is recommended for zinc deficiency. In clinical practice, polaprezinc has been used as a zinc replacement therapy for zinc deficiency. However, the efficacy of polaprezinc has not been established.
View Article and Find Full Text PDF